CONTEXT: Commercial announcement of yet another RWD tie-up. IMPACT: Low READ TIME: 1 min Quality Level Mean [1 – 10]: 2 1. “FAIRFAX, Va., April 7, 2021 /PRNewswire/ Continue Reading
CONTEXT: Latest update (8 April 2021) from LEEM describing the role of the QP PV | Must read! IMPACT: Medium READ TIME: 1 min Quality Level Mean [1 – 10]: Continue Reading
CONTEXT: Commercial announcement of another in what is becoming the biggest rend this year – access to RWD. I don’t know about you, but I’m intrigued by the phrase “research Continue Reading
CONTEXT: Prospective observational study in releasing remitting multiple sclerosis (RRMS) with a relatively old treatment showing a fairly content and stable patient population in Germany | Study conducted between 2015 Continue Reading
CONTEXT: This retrospective analysis of an at-home monitoring system gives hope for suffers of age-related macular degeneration (AMD) | The large sale analysis of US patients showed the system could Continue Reading
CONTEXT: Relatively small scale RWE study (102 patients) on the variation in biomarker testing in NSCLC patients in the Netherlands. IMPACT: Low READ TIME: 1 min Quality Level Mean [1 Continue Reading
CONTEXT: Market report on the still buoyant RWE market, or at least the valuations of the market are buoyant | Different day, different figure IMPACT: Low READ TIME: 1 min Continue Reading
CONTEXT: Early days in this incredibly worth while endeavour to use the newly emerging AI/ML tools to process patient data into research grade data. Created within this cholangiocarcinoma (bile duct Continue Reading
CONTEXT: One of those quirky stories that catch our interest every now and again. Who knows where this research will lead….? IMPACT: Low READ TIME: 2 mins Quality Level Mean Continue Reading
CONTEXT: They say cancer is the great leveller. Apparently not. This is a well put together, thought-provoking article highlighting the inequalities in cancer treatments and how RWR can help even Continue Reading
